Current and upcoming methods of pharmacotherapy of obesity
DOI:
https://doi.org/10.12775/JEHS.2023.13.04.028Keywords
obesity, anti-obesity drugs, overweight, glucagon-like peptide-1, body weight reduction, combination obesity pharmacotherapyAbstract
Introduction and purpose:
Obesity remains an urgent problem, both worldwide and in Poland. Approximately 25% of people in Poland are obese. Therefore, anti-obesity drugs are gaining clinical importance. The aim of this work is to describe new methods of pharmacotherapy of obesity and to give short description of the most promising research being
currently conducted in the topic.
Description of the state of knowledge
There are four drugs currently approved for the treatment of obesity in Poland. One of them, semaglutide is not practically available yet. While flozins probably will not be used in the therapy of obesity in patients without diabetes, there are some reseach showing their usefulness in combination with GLP-1 analogs. Tirzepatide, glucose-dependent insulinotropic peptide receptor agonist, has been recently approved in the EU and seems to be an effective anti-obesity agent. New substances extending its mechanism of action and further increasing effectiveness are during research. FGF21 is a catabolic peptide hormone, showing a beneficial pleiotropic effect. Gene therapy that increases endogenous FGF21 levels is being researched. Pharmacotherapy of obesity in Poland is not financed from the general health insurance, which makes the economical aspect an important one. While inhibitors of lipid absorption and tesofensine are two drugs which had been previously classified as unsuitable for the treatment of obesity, new research show that they may be effective; along with methylphenidate these three drugs may be more accessible in financial terms.
Conclusions
There are many new and emerging ant-obesity agents, which will be possibly used in Poland. Tirzepatide seems to be the most promising one so far. The usefulness of new agents must be considered in terms of economic availability.
References
Bąk‐Sosnowska M., Białkowska M., Bogdański P., Chomiuk T., Gałązka‐Sobotka M., Holecki M., Jarosińska A., Jezierska M., Kamiński P., Kłoda K., Kręgielska‐Narożna M., Lech M., Mamcarz A., Mastalerz‐Migas A., Matyjaszek‐Matuszek B., Ostrowska L., Pła WM. Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. Med Prakt wyd specj. Published online 2022:1-87.
Piwońska A, Piotrowski W, Kozela M, et al. Cardiovascular diseases prevention in Poland: results of WOBASZ and WOBASZ II studies. Kardiol Pol. 2018;76(11):1534-1541. doi:10.5603/KP.A2018.0154
Rutkowska M. Czy Polacy mają problem z nadwagą ? Cent Badań Opinii Społecznej. 2019;(103):1-4. https://www.cbos.pl/SPISKOM.POL/2019/K_103_19.PDF
Capodaglio P, Gobbi M, Donno L, et al. Effect of Obesity on Knee and Ankle Biomechanics during Walking. Sensors (Basel). 2021;21(21). doi:10.3390/S21217114
Rejestr Produktów Leczniczych. Dostęp internetowy pod adresem https://rejestrymedyczne.ezdrowie.gov.pl/rpl/search/public w dniach 2.12-29.12.2022.
Wegovy | European Medicines Agency. Accessed January 12, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/JAMA.2021.3224
Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/JAMA.2021.23619
Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019;79(3):219-230. doi:10.1007/S40265-019-1057-0
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/EURHEARTJ/EHAB368
Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042-1049. doi:10.1002/OBY.20663
Færch K, Blond MB, Bruhn L, et al. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. Diabetologia. 2021;64(1):42-55. doi:10.1007/S00125-020-05306-1
Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-1016. doi:10.1016/S2213-8587(16)30267-4
Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324-3328. doi:10.2337/DB13-0604
He YL, Haynes W, Meyers CD, et al. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 2019;21(6):1311-1321. doi:10.1111/DOM.13654
Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs. 2020;29(1):63-71. doi:10.1080/13543784.2020.1705277
de Boer RA, Núñez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020;86(7):1346-1356. doi:10.1111/BCP.14248
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMOA2107519/SUPPL_FILE/NEJMOA2107519_DATA-SHARING.PDF
Lilly goes head-to-head again, this time in obesity | Evaluate. Accessed January 15, 2023. https://www.evaluate.com/vantage/articles/news/corporate-strategy-snippets/lilly-goes-head-head-again-time-obesity
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities | Eli Lilly and Company. Accessed January 15, 2023. https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-fast-track-designation-tirzepatide
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/s0140-6736(22)02033-5
Brzozowski T. Konturek - Fizjologia Człowieka.; 2019.
Denison H, Nilsson C, Kujacic M, et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab. 2013;15(2):136-143. doi:10.1111/DOM.12002
Nakajima K, Chatelain R, Clairmont KB, et al. Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans. J Med Chem. 2017;60(11):4657-4664. doi:10.1021/ACS.JMEDCHEM.7B00173/SUPPL_FILE/JM7B00173_SI_002.PDF
Cheng D, Zinker BA, Luo Y, et al. MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. Cell Metab. 2022;34(11):1732-1748.e5. doi:10.1016/J.CMET.2022.10.007
Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-1643. doi:10.1038/IJO.2010.87
Saniona’s tesofensine meets primary and secondary endpoints. Accessed January 18, 2023. https://www.globenewswire.com/news-release/2018/12/17/1667781/0/en/Saniona-s-tesofensine-meets-primary-and-secondary-endpoints-in-Phase-3-obesity-registration-trial.html
Tesomet - Saniona. Accessed January 18, 2023. https://saniona.com/pipeline/tesomet/
Huynh K, Klose M, Krogsgaard K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700. doi:10.1530/EJE-21-0972
Medikinet. Charakterystyka produktu leczniczego. Pobrane ze strony Urzędu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych: https://leki.urpl.gov.pl/files/25_Medikinet_5_10_20_tabl_5_10_20.pdf.
Leddy JJ, Epstein LH, Jaroni JL, et al. Influence of methylphenidate on eating in obese men. Obes Res. 2004;12(2):224-232. doi:10.1038/OBY.2004.29
Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw open. 2021;4(1). doi:10.1001/JAMANETWORKOPEN.2020.33457
Garito T, Roubenoff R, Hompesch M, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab. 2018;20(1):94-102. doi:10.1111/DOM.13042
Jimenez V, Jambrina C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med. 2018;10(8). doi:10.15252/EMMM.201708791
Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2021;8(1):19-25. doi:10.1016/J.CDTM.2021.08.005
Gaich G, Chien JY, Fu H, et al. The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metab. 2013;18(3):333-340. doi:10.1016/J.CMET.2013.08.005
Bartesaghi S, Wallenius K, Hovdal D, et al. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. Mol Ther - Nucleic Acids. 2022;28:500-513. doi:10.1016/j.omtn.2022.04.010
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jan Bieniasz, Konrad Dendys, Marcel Kazzi, Michał Puła, Marta Wychota
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 923
Number of citations: 0